# Ovid Therapeutics Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Ovid Therapeutics Inc.). ## Overview Ovid Therapeutics Inc. is a U.S.-based biopharmaceutical company focused on developing small-molecule medicines for brain conditions with significant unmet need. Its business centers on discovering, developing, and seeking regulatory approval for therapies in epilepsy and other neurological disorders, often through internal programs and licensing or collaboration arrangements. ## Products & services • Small-molecule medicines for brain conditions • Drug discovery and preclinical development programs • Clinical-stage neurological drug candidates • Licensing and collaboration agreements • Regulatory and development-stage pipeline assets - **Neurology drug candidates** (0%) — Small-molecule therapies being developed for epilepsy and other brain disorders. - **Licensing and collaboration revenue** (100%) — Upfront, milestone, royalty, and other payments from partnered programs. - **Research and development programs** (0%) — Internal discovery, preclinical, and clinical development activities for pipeline assets. - Small-molecule medicines for brain conditions - Drug discovery and preclinical development programs - Clinical-stage neurological drug candidates - Licensing and collaboration agreements - Regulatory and development-stage pipeline assets ## Customers Ovid does not sell commercial drugs today; its economic counterparties are primarily licensing partners, collaborators, and research counterparties that fund or support development programs. If approved products are commercialized in the future, customers would shift to physicians, patients, and third-party payors in the relevant neurological disease markets. - **Licensing and collaboration partners** (primary) — Biopharma counterparties that license rights to Ovid programs or share development economics. - **Future prescribers** (secondary) — Neurologists and other specialists who would prescribe approved therapies based on efficacy and safety. - **Future patients and caregivers** (secondary) — Patients with epilepsy and other neurological disorders who would use approved medicines. - **Third-party payors** (secondary) — Commercial and government payors that influence access, coverage, and reimbursement. - Licensing partners that pay upfront, milestone, or royalty fees - Collaborators supporting development or commercialization rights - Future physicians treating epilepsy and other brain disorders - Future patients with rare or hard-to-treat neurological conditions - Third-party payors that determine reimbursement after approval ## Geography Ovid is headquartered in the United States and operates as a U.S.-based development-stage biopharmaceutical company. Its clinical and commercial exposure is primarily U.S.-centric, although clinical trials, regulatory interactions, and partnering activities may involve multiple countries. - Headquartered in the United States - Primary operating base is U.S. biopharma development - Clinical trials may be conducted in multiple countries - Future commercialization would depend on approved market geographies - Partnering and regulatory exposure can extend beyond the U.S. ## Strategy Ovid’s strategy is to advance a focused pipeline of small-molecule medicines for brain conditions with significant unmet need, using scientific and clinical data to decide which programs to fund. The company also seeks to create value through licensing and collaboration structures that can support development while preserving optionality for future commercialization. - **Advance clinical and preclinical neuroscience programs** (medium-term) — Pipeline progress is the main driver of future value in a development-stage biotech model. - **Use collaborations and licensing to fund development** (short-term) — Partnership economics can provide non-dilutive capital and external validation. - **Allocate capital selectively across programs** (short-term) — A focused funding approach helps concentrate resources on the most promising assets. - Advance small-molecule programs for epilepsy and other brain disorders - Prioritize programs with the strongest clinical and commercial potential - Use partnerships to support development and monetization - Generate value from licensing, milestones, and royalties - Manage pipeline funding based on scientific and clinical evidence ## Risks Ovid faces the core risks of a development-stage biotech company: clinical failure, regulatory delay, and uncertainty over whether approved therapies will gain market acceptance. It also depends on third parties for manufacturing and on external payors and regulators for reimbursement and commercialization, while competition in neuroscience can reduce the chance of success. - **Need for additional capital** [high] — Development-stage operations require ongoing funding and capital may not be available on acceptable terms. - **Clinical development failure** [high] — Drug candidates can fail on efficacy, safety, enrollment, or trial design. - **Regulatory approval risk** [high] — FDA and other regulators may delay, restrict, or deny approval. - **Third-party manufacturing dependence** [high] — The company does not own manufacturing facilities and relies on external suppliers. - **Reimbursement and market access risk** [medium] — Payor coverage and pricing can limit adoption even if a drug is approved. - **Competitive pressure** [high] — Larger pharma and biotech firms may develop better or faster therapies. - Clinical trials may fail or take longer than expected - Regulatory approval is uncertain and can be delayed - Third-party manufacturers create supply and quality risk - Competition may produce better or earlier therapies - Reimbursement may be limited or unavailable after approval - Small patient populations can make commercialization difficult ## Accounting The most important accounting issues for Ovid are revenue recognition from licensing and collaboration agreements, which can be lumpy and depend on milestone achievement and royalty timing. Investors should also watch estimates for accrued expenses, stock-based compensation, and any valuation changes tied to collaboration or royalty-related arrangements, since these can materially affect reported results in a development-stage company. - **Revenue recognition for licensing and collaboration agreements** — Can create uneven revenue recognition across periods - **Accrued clinical and development expenses** — Affects R&D expense and liabilities - **Stock-based compensation** — Impacts operating loss and comparability - **Royalty monetization or collaboration-related liabilities** — Can add volatility below operating income - License and collaboration revenue can be timing-sensitive and milestone-driven - Royalties depend on partner sales and can create uneven quarterly revenue - Accrued expenses require judgment for clinical and professional services - Stock-based compensation affects operating expense and non-cash results - Valuation changes in partnership-related liabilities can affect other income/expense --- *Last updated: 2026-04-29T04:44:45.715833+00:00*